Clinical Research Directory
Browse clinical research sites, groups, and studies.
Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk
Sponsor: University Hospital, Bordeaux
Summary
Systemic sclerosis (SSc) is a severe autoimmune disease associating dysimmunity, vasculopathy and fibrosis. No curative treatment is available. Pre-clinical abnormalities can be found such as specific autoantibodies. The association of Raynaud phenomenon and SSc-specific anti-nuclear antibodies is the hallmark of pre-scleroderma subjects, among who around 47% declare a complete disease after five years. The aim of this study is to assess in this particular population the preventive effect of an anti-platelet treatment.
Official title: Phase II/III Double-blind Randomized Placebo-controlled Trial Assessing the Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk in Subjects With Specific Dysimmunity and Raynaud Phenomenon
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2022-06-22
Completion Date
2031-06
Last Updated
2025-07-14
Healthy Volunteers
No
Conditions
Interventions
clopidogrel treatment
75 mg daily during 24 months
Placebo
75 mg daily during 24 months
Locations (10)
CH de la Cote Basque - service de rhumatologie
Bayonne, France
CHU de Bordeaux - service de Médecine Interne et Maladies Infectieuses
Bordeaux, France
CHU de Bordeaux - service de rhumatologie
Bordeaux, France
CHU de Brest - service de rhumatologie
Brest, France
CHU de Grenoble Alpes - service de médecine vasculaire
Grenoble, France
CH de Libourne - service de rhumatologie
Libourne, France
CH de Mont-de-Marsan - service de rhumatologie
Mont-de-Marsan, France
AP-HP - Hôpital Cochin - service de médecine interne
Paris, France
CH de Pau - service de médecine interne
Pau, France
CHU de Toulouse - service de médecine interne
Toulouse, France